Skip to main content
Psychedex
Article

Bromazepam Facts

Depressant; Anxiolytic; Benzodiazepine; GABA-A receptor positive allosteric modulator

Description

Bromazepam is a synthetic depressant of the benzodiazepine class. It amplifies GABA — the brain's main calming signal — making inhibitory receptors more responsive and producing anxiolysis, sedation, and muscle relaxation.[1]

Subjective effects include anxiety relief, muscle relaxation, sedation, and disinhibition. At lower doses, bromazepam produces a distinctive clarity — a loosening of social tension rather than heavy drowsiness[2] — but sedation and cognitive blunting increase with dose.

Bromazepam produces physical dependence with repeated use; alone, its acute lethality is low.[3] Every documented fatal case involved a combination with alcohol, opioids, or another depressant, which suppress breathing in ways the drug alone does not.

Dose and durationby route · individual sensitivity varies

Oral(mg)
Threshold< 1.5 mgLight1.5 – 3 mgCommon3 – 6 mgStrong6 – 12 mgHeavy12+ mg

Starts in 14 – 15 minLasts 6 – 15 hoursAfter-effects 12 – 22 hours

Body and dependence

Acute toxicity
Low
Chronic toxicity
High
Physical dependence
High
Psychological dependence
Moderate
Withdrawal
Severe · fatal · medical supervision
Compulsive redosing
Moderate

Tolerance

Builds
Moderate
Fully resets after
3 weeks
Carries over to
all benzodiazepines; alcohol; barbiturates; zolpidem; zopiclone

Effectslikely at a common dose

Perception
Dreaming suppression; +2 possible, including Visual acuity suppression, Vestibular distortion
Body
Sedation; Muscle relaxation; +8 possible, including Motor control impairment, Dizziness, Nystagmus (eye wobbles)
Thinking
none likely · 16 possible, including Memory suppression, Cognitive impairment, Analysis suppression
Feeling
Anxiety suppression; +2 possible
Self
none likely · 3 possible, including Communication suppression

Who shouldn't take it

Absolute
Severe respiratory depression; Sleep apnea syndrome; Myasthenia gravis; Hypersensitivity to benzodiazepines
Relative
History of substance use disorder; Hepatic impairment; First trimester of pregnancy; Elderly patients (>60 years); Concurrent CNS depressant use

Combinations60 recorded

Lethal (1)
Opioids
Dangerous (21)
Alpha-2 adrenergic receptor antagonist; Antipsychotics; Atypical antipsychotics; Benzodiazepines; Buprenorphine, Kratom; Cannabis, THC; Clonidine, Guanfacine; Gabapentin, Pregabalin; GHB, Baclofen; GHB, GBL; Local anesthetics; Naltrexone; SNRIs; Stimulants; Synthetic cannabinoids; Ibogaine; Ketamine, DXM, PCP; MAOIs; NSAIDs; Poppers (Alkyl nitrites); Poppers, Nitrates
Caution (26)
See full page: psychedex.org/substances/bromazepam
Not graded (12)
Not listed never means safe.

Seek help immediately if

  • Extreme drowsiness — can't stay awake or be roused
  • Confusion, slurred speech, severe loss of coordination
  • Slow, shallow, or irregular breathing
  • Unconsciousness / unresponsive; limp, floppy body
  • Blue lips or fingertips
  • Vomiting while sedated (choking / aspiration risk)
  • Cold, clammy skin; weak pulse

What to do

  1. Try to wake them — shout, firm sternal rub
  2. If unresponsive or breathing is impaired, call emergency services
  3. Place them in the recovery position — critical, they can choke on vomit
  4. Monitor breathing continuously; be ready to give rescue breaths / CPR
  5. Never leave them alone to "sleep it off"
  6. Do not give other drugs, stimulants, or more depressants

Most depressant overdoses resolve with airway protection, breathing support, and monitoring. The danger is respiratory depression and choking on vomit — sharply worse when combined with opioids or alcohol. GHB/GBL overdoses often involve sudden deep unconsciousness and may self-resolve, but airway protection is essential.

988 Suicide & Crisis LifelineFireside Project: 62-FIRESIDE

Version r1 · Not medical advice

References

  1. [1]
    ^Vieira MPS et al. (2022) First evaluation of the anxiolytic-like effects of a bromazepam-palladium complex in mice. — Journal of Inorganic Biochemistry doi:10.1016/j.jinorgbio.2022.112012
  2. [2]
    ^Cassano GB, Carrara S, Castrogiovanni P (1975) Bromazepam versus diazepam in psychoneurotic inpatients. — Pharmakopsychiatrie Neuro-Psychopharmakologie PMID:9648
  3. [3]
    ^Navarrete F, Marín-Mayor M, Martínez-Hostyn L, Rubio G, Manzanares J (2026) Benzodiazepine Dependence: Clinical and Molecular Aspects, Preventive Strategies and Therapeutic Approaches. — International journal of molecular sciences doi:10.3390/ijms27031430
Print version
Report an issue